It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.

As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.

Imekuwa wazi kwamba sasa za dawa utaratibu wa majina wa dawa za akili haionyeshi elimu yetu ya kisasa, wala gani kuwajulisha vizuri Daktari wa maagizo sayansi ya ubongo-msingi. Mara nyingi sana sisi kuagiza "dawamfadhaiko" kwa "wasiwasi" matatizo au "vizuia magonjwa ya akili kizazi cha pili" kwa wagonjwa huzuni.
Zoezi hili ni utata.
• Tano ya mashirika ya kimataifa ECNP, ACNP, AsCNP, CINP & IUPHAR aliamua miaka mitano iliyopita ya kuanzisha kikosi kazi na akampa kazi ya kupachika sayansi ya ubongo wetu wa sasa maendeleo katika utaratibu wa majina.
• wigo ni pamoja dawa zote na mifumo mingi dalili na kuunganisha utaratibu wa majina haya mapya ya kusaidia madaktari wakati wao ni kujaribu kufikiri nini itakuwa ya mantiki "hatua neuropsychopharmacological".
• Katika toleo hili la pili 22 dawa mpya ziliongezwa ili NBN pamoja sasa 130 dawa.
Hii utaratibu wa majina ya mapendekezo inalenga kutafakari sasa za dawa msingi wa elimu na wanaweza si lazima kuwakilisha mwisho kisayansi ukweli.
Jopokazi kwamba wamekusanyika wangeweza kuchukua msimamo kwamba elimu yetu ya sasa ya msingi haitoshi kuelezea lengo la msingi au taratibu sahihi wa utekelezaji. Lakini kama kikosi kazi, tunafikiri kwamba ni bora sasa avancerad kisayansi tafsiri ya kusubiri kwa hitimisho bainifu. Tunahitaji kutibu wagonjwa wetu sasa, na hatuwezi kuahirisha matibabu mpaka ukweli wote ni kujulikana.
 
Kwa hiyo utaratibu wa majina hii inatokana na:
1. haja ya kutibu sasa.
2. Updated sayansi ya ubongo utambuzi.
3. hukumu ya wajumbe wa kikosi kazi.
Katika suala hili, sisi kuja na pendekezo yafuatayo:
Utaratibu wa majina:
Pharmacology na Hali ya hatua - huonyesha ujuzi wa sasa na ufahamu kuhusu walengwa neurotransmitter / molekuli / system kuwa tarehe na hali ya / utaratibu wa utekelezaji.
 Pia aliongeza 4 mitazamo ya ziada
4 Vipimo ziada:
Approved Dalili - kulingana na mapendekezo ya miili mikubwa ya udhibiti (kwa mfano FDA, EMA, nk)
Utendakazi na Side Effects - Driven kutoka chanya moja, kubwa, RCT na / au "nzito imara uzito" data ya kliniki. Tu madhara umeenea au kutishia maisha upande ilijumuishwa
Vitendo Kumbuka - muhtasari maarifa ya kiafya ambayo imekuwa "kuchujwa" kupitia jopo kazi hilo "ungo"
Neurobiology - mwelekeo huu ulilenga biolojia. Imegawanywa katika sehemu ya kabla ya kutambuliwa na kliniki, kwa msisitizo juu ya mwisho
Kwa wale ambao ungependa kujua abo zaidi inayotokana na upimaji data.ut taaluma ya dawa, kuna uhusiano wa moja kwa moja na tovuti muhimu za IUPHAR - mshirika wetu katika jitihada hii.
 
Kama hii ni unaoendelea mchakato, tunatambua kwamba bidhaa si kamili. Kulingana na maoni yako (na kwa kuzingatia maoni ya vyuo vingine) ripoti mpya na matokeo, taarifa sahihi (kwa mfano baadaye matoleo) utafanywa.